Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  European Urology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.eururo.2009.04.046PMID 19446952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.

  2010cited by this paper
• Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.

  2009cited by this paper
• The economic impact of overactive bladder syndrome in six Western countries

  2009cited by this paper
• Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.

  2009cited by this paper
• A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

  2008cited by this paper
• The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis.

  2008cited by this paper
• Early effect on the overactive bladder symptoms following botulinum neurotoxin type A injections for detrusor overactivity.

  2008cited by this paper
• Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder.

  2007cited by this paper
• Long-Term Management of Overactive Bladder with Antimuscarinic Agents

  2007cited by this paper
• Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

  2006influential reference
• COX-2 inhibitors--a lesson in unexpected problems.

  2005cited by this paper
• Role of substance P in several models of bladder inflammation

  2004cited by this paper
• Substance P via NK1 receptor facilitates hyperactive bladder afferent signaling via action of ROS.

  2003cited by this paper
• Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder

  2003cited by this paper
• Effect of TAK-637, a tachykinin NK1-receptor antagonist, on lower urinary tract function in cats.

  2001cited by this paper
• Autoradiographic localization of tachykinin and calcitonin gene-related peptide receptors in adult urinary bladder.

  2000cited by this paper
• Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

  1999cited by this paper
• Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity.

  1999cited by this paper
• The MOS 36-Item Short form Health Survey

  1997cited by this paper
• Characterization of tachykinin NK2 receptors in human urinary bladder.

  1995cited by this paper
• Evidence for a role of tachykinins as sensory transmitters in the activation of micturition reflex.

  1993cited by this paper
• A VIP-containing system concentrated in the lumbosacral region of human spinal cord

  1983cited by this paper
• The human spinal cord: substance P and methionine-enkephalin immunoreactivity

  1982cited by this paper

• No citing papers are available for this paper.